Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 671 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Echocardiography, transthoracic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function

NCT00661323
View directory record Official record
Conditions
Ischemia, Myocardial Infarction, Ischemic Heart Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Not applicable Interventional

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

NCT05010109
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress Test, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Not applicable Interventional

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

NCT05848284
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Interventions
VDyne Transcatheter Tricuspid Valve Replacement System
Device
Lead sponsor
VDyne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Semaglutide Therapy in Heart Failure Patients

NCT06541509
View directory record Official record
Conditions
Heart Failure, Obesity
Interventions
Semaglutide
Drug
Lead sponsor
University Medical Centre Ljubljana
Other
Eligibility
20 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

NCT04214249
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Osimertinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Not applicable Interventional

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

NCT04147884
View directory record Official record
Conditions
Mitral Regurgitation Functional, Mitral Valve Disease, Cardiovascular Diseases
Interventions
Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Completed No phase listed Observational

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

NCT04200378
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Myocardial Blood Volume Measurement by Real-Time Myocardial Perfusion Echocardiography Correlates to Myocardial Compressibility by Cardiac Magnetic Resonance Imaging in Healthy Subjects

NCT04724304
View directory record Official record
Conditions
Healthy Adults
Interventions
Real-Time Myocardial Echocardiography (RTMPE), Magnetic resonance image (MRI)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional

A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs

NCT00327158
View directory record Official record
Conditions
Diaphyseal Femur Fracture
Interventions
Transesophageal transducer, echocardiography
Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
838
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

NCT02595944
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
884
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Completed No phase listed Observational

Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NCT00354328
View directory record Official record
Conditions
Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
20 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting No phase listed Observational

Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance

NCT07131631
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Minneapolis, Minnesota • Charlotte, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Completed No phase listed Observational

The Bronx-Valve Registry

NCT05453526
View directory record Official record
Conditions
Valvular Heart Disease
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
330,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Clinical Reminders in Test Reports to Improve Guideline Compliance

NCT01792544
View directory record Official record
Conditions
Echocardiography
Interventions
Statement, No Statement
Other
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
Not listed
Enrollment
1,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting No phase listed Observational

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

NCT07308704
View directory record Official record
Conditions
Cardiomyopathy, Ischemic Heart Disease, Cardiac Amyloidosis
Interventions
Transthoracic Echocardiography (TTE)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,040,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement

NCT04107038
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
General Endotracheal Anesthesia, Monitored anesthesia care
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

NCT07423585
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Tarlatamab
Procedure · Other · Drug
Lead sponsor
Asrar Alahmadi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Phase 1 Interventional

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

NCT06357182
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Biopsy, Echocardiography Test, Iadademstat, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

NCT03882359
View directory record Official record
Conditions
Heart Diseases
Interventions
Echocardiogram, MVT-100, Definity
Diagnostic Test · Drug
Lead sponsor
Microvascular Therapeutics, LLC
Industry
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Kansas City, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

NCT03983824
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:21 PM EDT